<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927067</url>
  </required_header>
  <id_info>
    <org_study_id>SHP620-302</org_study_id>
    <secondary_id>2015-004726-34</secondary_id>
    <nct_id>NCT02927067</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of maribavir to valganciclovir for the
      treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell
      transplant (HSCT) recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">July 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at the End of Study Week 8, Regardless of Whether Study Assigned Treatment was Completed</measure>
    <time_frame>Week 8</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations less than lower limit of quantification (LLOQ; i.e. &lt;137 International units per milliliter [IU/mL]), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. The participant must have received exclusively study-assigned treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Maintained Confirmed CMV Viremia Clearance Achieved at the End of Study Week 8 Through Study Week 16, Regardless of Whether Study Assigned Treatment was Completed</measure>
    <time_frame>Week 8 through Week 16</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations &lt;LLOQ (&lt;137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. It will be measured from plasma CMV DNA by quantitative PCR assay. The participant must have received exclusively study-assigned treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Confirmed CMV Viremia Clearance After 8 Weeks of Receiving Study-assigned Treatment</measure>
    <time_frame>Week 8</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations &lt;LLOQ (&lt;137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. It will be measured from plasma CMV DNA by quantitative PCR assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Maintained Confirmed CMV Viremia Clearance After Completion of 8 Weeks of Receiving Study-Assigned Treatment Through Study Weeks 12, 16 and 20</measure>
    <time_frame>Week 8 through Weeks 12, 16 and 20</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations &lt;LLOQ (&lt;137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. It will be measured from plasma CMV DNA by quantitative PCR assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Maintained Confirmed CMV Viremia Clearance After Completion of 8 Weeks of Receiving Study-Assigned Treatment Through Study Weeks 12, 16 and 20 Regardless of Whether Study Assigned Treatment was Completed</measure>
    <time_frame>Week 8 through Weeks 12, 16 and 20</time_frame>
    <description>Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations &lt;LLOQ (&lt;137 IU/mL), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. It will be measured from plasma CMV DNA by quantitative PCR assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Confirmed Recurrence of Viremia While on Study Treatment and Off Treatment</measure>
    <time_frame>Baseline up to Week 20</time_frame>
    <description>Recurrence of CMV viremia is defined as plasma CMV DNA concentration greater than or equal to (&gt;=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma samples at least 5 days apart, after being unquantifiable (&lt;LLOQ) for at least 5 days in 2 consecutive samples during the first 8 weeks of the study, during the 12 weeks of the followup study phase, and at any time during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 or 4 Neutropenia</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>Grade 3 and grade 4 neutropenia are defined as absolute neutophil count (ANC) &lt; 1000 per cubic millimeter (/mm^3) and ANC &lt; 500/mm^3 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>Baseline up to Week 20</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE that has a start date on or after the first dose of study treatment, or that has a start date before the date of first dose of study treatment but increases in severity after the first dose of study treatment, will be considered a treatment-emergent AE (TEAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Concentration (Cmin) of Maribavir</measure>
    <time_frame>Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1</time_frame>
    <description>Cmin of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve Over the 12-Hour Dosing Interval at Steady State AUC(0-tau) of Maribavir</measure>
    <time_frame>Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1</time_frame>
    <description>AUC(0-tau) of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Maribavir</measure>
    <time_frame>Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1</time_frame>
    <description>Cmax of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time When Maximum Concentration is Observed (Tmax) of Maribavir</measure>
    <time_frame>Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1</time_frame>
    <description>Tmax of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Maribavir</measure>
    <time_frame>Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1</time_frame>
    <description>CL/F of Maribavir will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of Maribavir</measure>
    <time_frame>Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1</time_frame>
    <description>Vz/F of Maribavir will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Cytomegalovirus (CMV)</condition>
  <arm_group>
    <arm_group_label>Maribavir/ Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 400 milligrams (mg) of maribavir (2*200 mg tablets) twice daily (BID) orally along with a placebo matched to valganciclovir for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valganciclovir/ Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 900 mg of valganciclovir (2*450 mg tablets) BID orally along with a placebo matched to maribavir for 8 weeks. Valganciclovir dose may be adjusted to 450 mg BID or 450 mg QD during the study for renal function impairment or neutropenia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maribavir</intervention_name>
    <description>Participants will receive 400 mg of maribavir BID orally.</description>
    <arm_group_label>Maribavir/ Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Participants will receive valganciclovir tablets orally.</description>
    <arm_group_label>Valganciclovir/ Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo tablets matched to either maribavir or valganciclovir.</description>
    <arm_group_label>Maribavir/ Placebo</arm_group_label>
    <arm_group_label>Valganciclovir/ Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be able to provide written, personally signed, and dated informed consent to
             participate in the study before completing any study-related procedures. As
             applicable, a parent/both parents or legally authorized representative (LAR) must
             provide signature of informed consent and there must be documentation of assent by the
             participants before completing any study-related procedures.

          -  Be greater than or equal to (&gt;=) 16 years of age at the time of consent.

          -  Be a recipient of hematopoietic stem cell transplant.

          -  Have a documented asymptomatic CMV infection, with a screening value of CMV DNA &gt;=1365
             International Units per millilitre (IU/mL) to less than or equal to (&lt;=) 273000 IU/mL
             in whole blood or &gt;= 455 IU/mL to &lt;= 91000 IU/mL in plasma in 2 consecutive
             assessments, separated by at least 1 day, as determined by local or central specialty
             laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative
             CMV DNA results. Both samples should be taken within 14 days prior to randomization
             with second sample obtained within 5 days prior to randomization. Same laboratory and
             same sample type (whole blood or plasma) should be used for these assessments.
             Asymptomatic CMV infection is defined as an infection that does not present with
             tissue invasive CMV disease, as assessed by the investigator. Participants with CMV
             DNA less than (&lt;) 910 and &gt;= 455 IU/mL in plasma or &lt; 2730 and &gt;= 1365 IU/mL in whole
             blood will also need to meet at least 1 of the following criteria for high-risk CMV
             infection to be eligible:

               1. Human leukocyte antigen (HLA)-related (sibling) donor with at least 1 mismatch at
                  1 of the following 3 HLA-gene loci: HLA-A, -B or -DR,

               2. Haploidentical donor

               3. Unrelated donor with at least 1 mismatch at 1 of the following 4 HLA -gene loci:
                  HLA-A, -B, -C and -DRB1,

               4. Use of umbilical cord blood as stem cell source,

               5. Use of ex vivo T-cell-depleted grafts,

               6. Grade 2 or greater graft-versus-host-disease (GVHD), requiring the use of
                  systemic corticosteroids (defined as the use of &gt;= 1 milligram per kilogram per
                  day (mg/kg/day) of prednisone or equivalent dose of another corticosteroid).

          -  Have the current CMV infection as the first episode of CMV viremia after HSCT, either
             primary or reactivation, which in the investigator's opinion requires treatment.

          -  Per investigator's judgment, be eligible for treatment with valganciclovir.

          -  Have all of the following results as part of screening laboratory assessments (results
             from either the central laboratory or a local laboratory can be used for
             qualification):

               1. Absolute neutrophil count to &gt;= 1000 per cubic millimeter (/mm^3) [1.0 x 10^9/L].

               2. Platelet count &gt;= 25,000/mm^3 [25 x 10^9/L].

               3. Hemoglobin &gt;= 8 grams per deciliter (g/dL).

               4. Estimated creatinine clearance &gt;=30 milliliters per minute (mL/min).

          -  Have a negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy test at
             screening, if a female of child bearing potential. Urine pregnancy tests may be done
             per institutional requirements; however they are not sufficient for eligibility
             determination. Sexually active females of child bearing potential must agree to comply
             with any applicable contraceptive requirements of the protocol. If male, must agree to
             use an acceptable method of birth control, as defined in the protocol, during the
             study treatment administration period and for 90 days afterward the last dose of study
             treatment.

          -  Be able to swallow tablets.

          -  Have life expectancy of &gt;= 8 weeks.

          -  Weigh &gt;= 40 kilograms (kg).

          -  Be willing and have an understanding and ability to fully comply with study procedures
             and restrictions defined in the protocol.

        Exclusion Criteria:

          -  Have CMV tissue invasive disease as assessed by the investigator at the time of
             screening and randomization at Visit 2/Day 0.

          -  Have a CMV infection that is known to be genotypically resistant to ganciclovir,
             valganciclovir, foscarnet, or cidofovir based on documented evidence.

          -  Be presenting with recurrent CMV infection (defined as a new detection of CMV
             infection in a participants who had at least one previously documented episode of CMV
             infection post-transplant, and who has had at least 2 weeks of undetectable CMV DNA
             between the episodes during active surveillance, based on same local laboratory and
             same sample type). The Participants must also have been off any anti-CMV treatment
             between the current and prior infection. Otherwise, the current infection may be
             considered continuation of the prior infection.

          -  Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for
             conditions other than CMV when study treatment is initiated (example: herpes simplex
             virus [HSV] co-infection requiring use of any of these agents after the randomization)
             or would need a co-administration with maribavir for CMV infection.

          -  Be receiving leflunomide, letermovir, or artesunate when study treatment is initiated.

        Note: Participants who may be receiving leflunomide must discontinue the use at least 14
        days prior to randomization at Visit 2/Day 0 and the first dose of study treatment.
        Participants receiving letermovir must discontinue use 3 days prior to first dose of study
        treatment. Participants receiving artesunate must discontinue the use prior to the first
        dose of study treatment.

          -  Be on treatment with anti-CMV agents (ganciclovir, valganciclovir, foscarnet or
             cidofovir) for the current CMV infection for longer than 72 hours.

          -  Have known hypersensitivity to the active substance or to an excipient of the study
             treatments.

          -  Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24
             hours prior to the first dose of study treatment that would preclude administration of
             oral medication.

          -  Require mechanical ventilation or vasopressors for hemodynamic support at the time of
             randomization.

          -  Be female and pregnant or nursing.

          -  Have previously completed, discontinued, or have been withdrawn from this study.

          -  Have received any investigational agent with known anti-CMV activity within 30 days
             before initiation of study treatment or CMV vaccine at any time.

          -  Have received any unapproved agent or device within 30 days before initiation of study
             treatment.

          -  Have any clinically significant medical or surgical condition that, in the
             investigator's opinion, could interfere with interpretation of study results,
             contraindicate the administration of the assigned study treatment, or compromise the
             safety or well-being of the participant.

          -  Have previously received maribavir.

          -  Have serum aspartate aminotransferase (AST) greater than (&gt;) 5 times upper limit of
             normal (ULN) at screening, or serum alanine aminotransferase (ALT) &gt; 5 times ULN at
             screening, or total bilirubin &gt;= 3.0 x ULN at screening (except for documented
             Gilbert's syndrome), as analyzed by local or central lab.

          -  Have known (previously documented) positive results for human immunodeficiency virus
             (HIV). Participants must have a confirmed negative HIV test result within 3 months of
             study entry or, if unavailable, be tested by a local laboratory during the screening
             period.

          -  Have active malignancy with the exception of nonmelanoma skin cancer, as determined by
             the investigator. Participants who experience relapse or progression of their
             underlying malignancy (for which HSCT was performed), as determined by the
             investigator, are not to be enrolled.

          -  Be undergoing treatment for acute or chronic hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>866-842-5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>310-825-6264</phone>
      <email>dwinston@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Drew Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>650-868-8073</phone>
      <email>wesbrown@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Janice Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>203-785-3561</phone>
      <email>maricar.malinis@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Maricar Malinis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>404-712-2051</phone>
      <email>gmlyon@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Lyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>708-327-3157</phone>
      <email>Patrick.Hagen@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Hagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>410-328-0386</phone>
      <phone_ext>6</phone_ext>
      <email>jyared@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Yared, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>443-287-4694</phone>
      <email>ravery4@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Robin Avery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>617-732-8881</phone>
      <email>fmarty@partners.org</email>
    </contact>
    <investigator>
      <last_name>Francisco Marty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>617-732-8881</phone>
      <email>fmarty@partners.org</email>
    </contact>
    <investigator>
      <last_name>Francisco Marty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>508-856-1978</phone>
      <email>laura.gibson@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>313-916-2573</phone>
      <email>galanga1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>George Alangaden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>612-625-8642</phone>
      <email>vanbu004@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jo-Anne Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>59905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>551-996-5234</phone>
      <email>scott.rowley@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Scott Rowley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joan and sandford I. Weill Medical College of Cornell University Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>212-746-2646</phone>
      <email>tbs2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Tsiporah Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>212-639-8361</phone>
      <email>papanicg@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Genovefa Papanicolaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>215-662-7066</phone>
      <email>blumbere@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Blumberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TriStar Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Saint Davids South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System - NAVREF</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>206-764-2969</phone>
      <email>tchaunce@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Chauncey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical College of Wisconsin, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>414-805-4600</phone>
      <email>phari@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Parameswaran Hari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61870740000</phone>
      <email>deepak.singhal@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Deepak Singhal, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61393429407</phone>
      <email>joe.sasadeusz@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Joe Sasadeusz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3238213250</phone>
      <email>alain.gadisseur@uza.be</email>
    </contact>
    <investigator>
      <last_name>Alain Gadisseur, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <state>Brussels</state>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3225413706</phone>
      <email>mickael.aoun@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Mickaël Aoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <state>Brussels</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3227641809</phone>
      <email>xavier.poire@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Xavier Poiré, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3293326654</phone>
      <email>tessa.kerre@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Tessa Kerre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3216346880</phone>
      <email>johan.maertens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Johan Maertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3250453061</phone>
      <email>dominik.selleslag@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Dominik Selleslag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3243667201</phone>
      <email>e.willems@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Evelyne Willems, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(604) 875-4588</phone>
      <email>alissa.wright@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Alissa Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(905) 521-2100</phone>
      <phone_ext>42199</phone_ext>
      <email>haider@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Shariq Haider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+38598230220</phone>
      <email>rvrhovac@mef.hr</email>
    </contact>
    <investigator>
      <last_name>Radovan Vrhovac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Prague</city>
        <state>Praha, Hlavní Mesto</state>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+420224436433</phone>
      <email>petr.sedlacek@lfmotol.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Sedlacek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ustav hematologie a krevni transfuze</name>
      <address>
        <city>Praha</city>
        <zip>128 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(420) 221-9772</phone>
      <phone_ext>96</phone_ext>
      <email>marketa.markova@uhkt.cz</email>
    </contact>
    <investigator>
      <last_name>Marketa Stastna Markova, MD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg Cedex</city>
        <state>Bas-Rhin</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <state>Gironde</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33557656511</phone>
      <email>laurence.clement@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Clement, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>GRENOBLE Cedex 9</city>
        <state>Isère</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3347676757563409</phone>
      <email>athiebautbertrand@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Thiebaut-Bertrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33240083994</phone>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers Cedex 9</city>
        <state>Maine-et-Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+332413544724475</phone>
      <email>syfrancois@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie Francois, MD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <state>Val-de-Marne</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33149812057</phone>
      <email>catherine.cordonnier@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Cordonnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besnçon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33381668232</phone>
      <email>edeconinck@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Deconinck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33555058039</phone>
      <email>pascal.turlure@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Turlure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Nice</city>
        <zip>7120</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33142499639</phone>
      <email>david.michonneau@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>David Michonneau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EDOG - Institut Claudius Regaud - PPDS</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33531156354</phone>
      <email>huynh.anne@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Huynh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universität des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4968411615000</phone>
      <email>niels.murawski@uks.eu</email>
    </contact>
    <investigator>
      <last_name>Niels Murawski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+493419713020</phone>
      <email>georg-nikolaus.franke@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Georg-Nikolaus Franke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site contact</last_name>
      <phone>+498214002353</phone>
      <email>christoph.schmid@klinikum-augsburg.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Schmid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13150</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4930940152151</phone>
      <email>herrad.baurmann@helios-gesundheit.de</email>
    </contact>
    <investigator>
      <last_name>Herrad Baurmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin Luther Universitat Halle Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+493455577250</phone>
      <email>lutz.mueller@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Lutz Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4940741055250</phone>
      <email>m.christopeit@uke.de</email>
    </contact>
    <investigator>
      <last_name>Maximilian Christopeit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+493814947421</phone>
      <email>christian.junghanss@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Christian Junghanß, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4971181015431</phone>
      <email>martin.kaufmann@rbk.de</email>
    </contact>
    <investigator>
      <last_name>Martin Kaufmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4970712982711</phone>
      <email>wolfgang.bethge@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Bethge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Del-pesti Centrumkorhaz- Orszagos Hematologiai és Infektologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3614558100</phone>
      <phone_ext>8603</phone_ext>
      <email>gopcsa.laszlo@dpckorhaz.hu</email>
    </contact>
    <investigator>
      <last_name>Laszlo Gopcsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390113135230</phone>
      <email>franca.fagioli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Di Verona</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390458124443</phone>
      <email>cristina.tecchio@univr.it</email>
    </contact>
    <investigator>
      <last_name>Cristina Tecchio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Dell'Angelo</name>
      <address>
        <city>Zelarino</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+393471226642</phone>
      <email>cutini.ilaria@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ilaria Cutini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3902550333353742</phone>
      <email>fonida@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francesco Onida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+393355267999</phone>
      <email>patrizia.chiusolo@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Patrizia Chiusolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(888) 888-8888</phone>
      <email>abusca.clinicaltrials@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alessandro Busca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sung Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Young Rok Do, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+6493737599</phone>
      <email>p.browett@auckland.ac.nz</email>
    </contact>
    <investigator>
      <last_name>Peter Browett, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canterbury Health Laboratories</name>
      <address>
        <city>Christchurch</city>
        <state>South Island</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+6433640392</phone>
      <email>andrew.butler@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Andrew Butler, MB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48717842576</phone>
      <email>wrobel.t@onet.pl, twrobel@usk.wroc.pl</email>
    </contact>
    <investigator>
      <last_name>Tomasz Wrobel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp z o o</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48225725959</phone>
      <email>wieslaw.jedrzejczak@wum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Wieslaw Jedrzejczak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne - PPDS</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48583493079</phone>
      <email>mbienia@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Maria Bieniaszewska, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+656321470</phone>
      <email>liang_piu_koh@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Liang Piu Koh, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital (SGH)</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+6563214722</phone>
      <email>aloysius.ho.y.l@sgh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Aloysius Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34934978987</phone>
      <email>cferra@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Christelle Ferra Coll, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34942202520</phone>
      <email>maranzazu.bermudez@scsalud.es</email>
    </contact>
    <investigator>
      <last_name>María Aranzazu Bermúdez Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca - H. Clinico</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34923291316</phone>
      <email>lvazlo@usal.es</email>
    </contact>
    <investigator>
      <last_name>Maria Lourdes Vazquez Lopez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site contact</last_name>
      <phone>+34932746414</phone>
      <email>pbarba@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Pere Barba Suñol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO l'Hospitalet - Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908-</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34932607750</phone>
      <email>rparody@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Rocio Parody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.H. Regional Reina Sofia - PPDS</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34957012972</phone>
      <email>rrojashurs@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Rojas Contreras, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34958020379</phone>
      <email>manuel.jurado.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Jurado Chacón, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34915202316</phone>
      <email>jrcamara@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Rafael De la Camara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34913368362</phone>
      <email>jlopezj.hrc@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier Lopez Jimenez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34911917809</phone>
      <email>rduarte.work@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Duarte Palomino, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga - Hospital General</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34942202520</phone>
      <email>ai.gallardomorillo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Gallardo Morillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>San Sebastian Gipuzkoa</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34943007041</phone>
      <email>OSID.ZERBITZUHEMATOLOGIA-TPH@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Juan Carlos Vallejo Llamas, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34963862625</phone>
      <email>csolano.work@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Solano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34961245876</phone>
      <email>sanz_jai@gva.es</email>
    </contact>
    <investigator>
      <last_name>Jaime Sanz Caballer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+41442553712</phone>
      <email>nicolas.mueller@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Nicolas Mueller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baskent University Medical Faculty Adana Practice and Research Center</name>
      <address>
        <city>Adana</city>
        <zip>1250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+00905322366797</phone>
      <email>hakanozdogu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hakan Ozdogu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ankara University Medica Faculty Hematology Department Clinical Research Area PPDS</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+903125957375</phone>
      <email>gurman@medicine.ankara.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Gunhan Gurman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>West Midlands</city>
        <state>Birmingham</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441214243699</phone>
      <email>bhuvan.kishore@heartofengland.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Bhuvan Kishore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+442083835101</phone>
      <email>dragana.milojkovic@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Dragana Milojkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+442076796236</phone>
      <email>karl.peggs@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Karl Peggs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>Tooting</city>
        <state>London</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+442087253545</phone>
      <email>mickey.koh@stgeorges.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mickey Koh, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441517064639</phone>
      <email>rahuman.salim@rlbuht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rahuman Salim, MB, MRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust - PPDS</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+441614463869</phone>
      <email>adrian.bloor@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Adrian Bloor, BA, MB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+442381204163</phone>
      <email>k.h.orchard@southampton.ac.uk; kho@soton.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Kim Orchard, BSc, MB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Maribavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

